Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy
Gastric carcinogenesis is a commonly diagnosed type of cancer and has a dismal prognosis because of the rate at which it aggressively spreads and because of the lack of effective therapies to stop its progression. This study evaluated a type of oral drug delivery system of a potential target-activat...
Gespeichert in:
| Veröffentlicht in: | Biomacromolecules 2015-09, Vol.16 (9), p.3021-3032 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3032 |
|---|---|
| container_issue | 9 |
| container_start_page | 3021 |
| container_title | Biomacromolecules |
| container_volume | 16 |
| creator | Lin, Yu-Hsin Chen, Zih-Rou Lai, Chih-Ho Hsieh, Chia-Hung Feng, Chun-Lung |
| description | Gastric carcinogenesis is a commonly diagnosed type of cancer and has a dismal prognosis because of the rate at which it aggressively spreads and because of the lack of effective therapies to stop its progression. This study evaluated a type of oral drug delivery system of a potential target-activated nanosizer comprising a fucose-conjugated chitosan and polyethylene glycol-conjugated chitosan complex with gelatin containing encapsulated green tea polyphenol extract epigallocatechin-3-gallate, allowing oral administration of the drug through a site-specific release in gastric cancer cells. The results demonstrated that the nanoparticles effectively reduced drug release within gastric acids and that a controlled epigallocatechin-3-gallate release inhibited gastric cancer cell growth, induced cell apoptosis, and reduced vascular endothelial growth factor protein expression. Furthermore, in vivo assay results indicated that the prepared epigallocatechin-3-gallate-loaded fucose-chitosan/polyethylene glycol-chitosan/gelatin nanoparticles significantly affected gastric tumor activity and reduced gastric and liver tissue inflammatory reaction in an orthotopic gastric tumor mouse model. |
| doi_str_mv | 10.1021/acs.biomac.5b00907 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727695301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1727695301</sourcerecordid><originalsourceid>FETCH-LOGICAL-a375t-bd25440fed4d9c81be3a6a68982f2ede27615bb2331cec76b45b2e68a3bbe03b3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0E4v0DLJCXbFL8iO1kWVW8pIpuyjoaOxNwlcTFTpH696S0sGQ1M9K5V5pDyA1nE84EvweXJtaHDtxEWcZKZo7IOVdCZ7lm4vhnV5kxpTkjFymt2MjIXJ2SM6FFoQ3n52QxdYP_QrqE-I4D1vQV-rCGOHjXYqJNiHQRoaXTuvO9T0OEwYeehoY-wXh5R2fQO4x0-YER1tsrctJAm_D6MC_J2-PDcvaczRdPL7PpPANp1JDZWqg8Zw3WeV26gluUoEEXZSEagTUKo7myVkjJHTqjba6sQF2AtBaZtPKS3O171zF8bjANVeeTw7aFHsMmVdyMFaWSjI-o2KMuhpQiNtU6-g7ituKs2omsRpHVXmR1EDmGbg_9G9th_Rf5NTcCkz2wC6_CJvbju_81fgPiVIFZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1727695301</pqid></control><display><type>article</type><title>Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy</title><source>ACS Publications</source><source>MEDLINE</source><creator>Lin, Yu-Hsin ; Chen, Zih-Rou ; Lai, Chih-Ho ; Hsieh, Chia-Hung ; Feng, Chun-Lung</creator><creatorcontrib>Lin, Yu-Hsin ; Chen, Zih-Rou ; Lai, Chih-Ho ; Hsieh, Chia-Hung ; Feng, Chun-Lung</creatorcontrib><description>Gastric carcinogenesis is a commonly diagnosed type of cancer and has a dismal prognosis because of the rate at which it aggressively spreads and because of the lack of effective therapies to stop its progression. This study evaluated a type of oral drug delivery system of a potential target-activated nanosizer comprising a fucose-conjugated chitosan and polyethylene glycol-conjugated chitosan complex with gelatin containing encapsulated green tea polyphenol extract epigallocatechin-3-gallate, allowing oral administration of the drug through a site-specific release in gastric cancer cells. The results demonstrated that the nanoparticles effectively reduced drug release within gastric acids and that a controlled epigallocatechin-3-gallate release inhibited gastric cancer cell growth, induced cell apoptosis, and reduced vascular endothelial growth factor protein expression. Furthermore, in vivo assay results indicated that the prepared epigallocatechin-3-gallate-loaded fucose-chitosan/polyethylene glycol-chitosan/gelatin nanoparticles significantly affected gastric tumor activity and reduced gastric and liver tissue inflammatory reaction in an orthotopic gastric tumor mouse model.</description><identifier>ISSN: 1525-7797</identifier><identifier>EISSN: 1526-4602</identifier><identifier>DOI: 10.1021/acs.biomac.5b00907</identifier><identifier>PMID: 26286711</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Administration, Oral ; Animals ; Apoptosis ; Catechin - analogs & derivatives ; Catechin - chemistry ; Catechin - pharmacology ; Chitosan - chemistry ; Chitosan - pharmacology ; Drug Carriers - chemistry ; Drug Carriers - pharmacology ; Gelatin - chemistry ; Gelatin - pharmacology ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Nanoparticles - chemistry ; Neoplasms, Experimental - drug therapy ; Neoplasms, Experimental - metabolism ; Neoplasms, Experimental - pathology ; Polyethylene Glycols - chemistry ; Polyethylene Glycols - pharmacology ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - pathology</subject><ispartof>Biomacromolecules, 2015-09, Vol.16 (9), p.3021-3032</ispartof><rights>Copyright © 2015 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a375t-bd25440fed4d9c81be3a6a68982f2ede27615bb2331cec76b45b2e68a3bbe03b3</citedby><cites>FETCH-LOGICAL-a375t-bd25440fed4d9c81be3a6a68982f2ede27615bb2331cec76b45b2e68a3bbe03b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.biomac.5b00907$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.biomac.5b00907$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26286711$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Yu-Hsin</creatorcontrib><creatorcontrib>Chen, Zih-Rou</creatorcontrib><creatorcontrib>Lai, Chih-Ho</creatorcontrib><creatorcontrib>Hsieh, Chia-Hung</creatorcontrib><creatorcontrib>Feng, Chun-Lung</creatorcontrib><title>Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy</title><title>Biomacromolecules</title><addtitle>Biomacromolecules</addtitle><description>Gastric carcinogenesis is a commonly diagnosed type of cancer and has a dismal prognosis because of the rate at which it aggressively spreads and because of the lack of effective therapies to stop its progression. This study evaluated a type of oral drug delivery system of a potential target-activated nanosizer comprising a fucose-conjugated chitosan and polyethylene glycol-conjugated chitosan complex with gelatin containing encapsulated green tea polyphenol extract epigallocatechin-3-gallate, allowing oral administration of the drug through a site-specific release in gastric cancer cells. The results demonstrated that the nanoparticles effectively reduced drug release within gastric acids and that a controlled epigallocatechin-3-gallate release inhibited gastric cancer cell growth, induced cell apoptosis, and reduced vascular endothelial growth factor protein expression. Furthermore, in vivo assay results indicated that the prepared epigallocatechin-3-gallate-loaded fucose-chitosan/polyethylene glycol-chitosan/gelatin nanoparticles significantly affected gastric tumor activity and reduced gastric and liver tissue inflammatory reaction in an orthotopic gastric tumor mouse model.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Catechin - analogs & derivatives</subject><subject>Catechin - chemistry</subject><subject>Catechin - pharmacology</subject><subject>Chitosan - chemistry</subject><subject>Chitosan - pharmacology</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Carriers - pharmacology</subject><subject>Gelatin - chemistry</subject><subject>Gelatin - pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplasms, Experimental - drug therapy</subject><subject>Neoplasms, Experimental - metabolism</subject><subject>Neoplasms, Experimental - pathology</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Polyethylene Glycols - pharmacology</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - pathology</subject><issn>1525-7797</issn><issn>1526-4602</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0E4v0DLJCXbFL8iO1kWVW8pIpuyjoaOxNwlcTFTpH696S0sGQ1M9K5V5pDyA1nE84EvweXJtaHDtxEWcZKZo7IOVdCZ7lm4vhnV5kxpTkjFymt2MjIXJ2SM6FFoQ3n52QxdYP_QrqE-I4D1vQV-rCGOHjXYqJNiHQRoaXTuvO9T0OEwYeehoY-wXh5R2fQO4x0-YER1tsrctJAm_D6MC_J2-PDcvaczRdPL7PpPANp1JDZWqg8Zw3WeV26gluUoEEXZSEagTUKo7myVkjJHTqjba6sQF2AtBaZtPKS3O171zF8bjANVeeTw7aFHsMmVdyMFaWSjI-o2KMuhpQiNtU6-g7ituKs2omsRpHVXmR1EDmGbg_9G9th_Rf5NTcCkz2wC6_CJvbju_81fgPiVIFZ</recordid><startdate>20150914</startdate><enddate>20150914</enddate><creator>Lin, Yu-Hsin</creator><creator>Chen, Zih-Rou</creator><creator>Lai, Chih-Ho</creator><creator>Hsieh, Chia-Hung</creator><creator>Feng, Chun-Lung</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20150914</creationdate><title>Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy</title><author>Lin, Yu-Hsin ; Chen, Zih-Rou ; Lai, Chih-Ho ; Hsieh, Chia-Hung ; Feng, Chun-Lung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a375t-bd25440fed4d9c81be3a6a68982f2ede27615bb2331cec76b45b2e68a3bbe03b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Catechin - analogs & derivatives</topic><topic>Catechin - chemistry</topic><topic>Catechin - pharmacology</topic><topic>Chitosan - chemistry</topic><topic>Chitosan - pharmacology</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Carriers - pharmacology</topic><topic>Gelatin - chemistry</topic><topic>Gelatin - pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplasms, Experimental - drug therapy</topic><topic>Neoplasms, Experimental - metabolism</topic><topic>Neoplasms, Experimental - pathology</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Polyethylene Glycols - pharmacology</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Yu-Hsin</creatorcontrib><creatorcontrib>Chen, Zih-Rou</creatorcontrib><creatorcontrib>Lai, Chih-Ho</creatorcontrib><creatorcontrib>Hsieh, Chia-Hung</creatorcontrib><creatorcontrib>Feng, Chun-Lung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Biomacromolecules</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Yu-Hsin</au><au>Chen, Zih-Rou</au><au>Lai, Chih-Ho</au><au>Hsieh, Chia-Hung</au><au>Feng, Chun-Lung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy</atitle><jtitle>Biomacromolecules</jtitle><addtitle>Biomacromolecules</addtitle><date>2015-09-14</date><risdate>2015</risdate><volume>16</volume><issue>9</issue><spage>3021</spage><epage>3032</epage><pages>3021-3032</pages><issn>1525-7797</issn><eissn>1526-4602</eissn><abstract>Gastric carcinogenesis is a commonly diagnosed type of cancer and has a dismal prognosis because of the rate at which it aggressively spreads and because of the lack of effective therapies to stop its progression. This study evaluated a type of oral drug delivery system of a potential target-activated nanosizer comprising a fucose-conjugated chitosan and polyethylene glycol-conjugated chitosan complex with gelatin containing encapsulated green tea polyphenol extract epigallocatechin-3-gallate, allowing oral administration of the drug through a site-specific release in gastric cancer cells. The results demonstrated that the nanoparticles effectively reduced drug release within gastric acids and that a controlled epigallocatechin-3-gallate release inhibited gastric cancer cell growth, induced cell apoptosis, and reduced vascular endothelial growth factor protein expression. Furthermore, in vivo assay results indicated that the prepared epigallocatechin-3-gallate-loaded fucose-chitosan/polyethylene glycol-chitosan/gelatin nanoparticles significantly affected gastric tumor activity and reduced gastric and liver tissue inflammatory reaction in an orthotopic gastric tumor mouse model.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>26286711</pmid><doi>10.1021/acs.biomac.5b00907</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-7797 |
| ispartof | Biomacromolecules, 2015-09, Vol.16 (9), p.3021-3032 |
| issn | 1525-7797 1526-4602 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1727695301 |
| source | ACS Publications; MEDLINE |
| subjects | Administration, Oral Animals Apoptosis Catechin - analogs & derivatives Catechin - chemistry Catechin - pharmacology Chitosan - chemistry Chitosan - pharmacology Drug Carriers - chemistry Drug Carriers - pharmacology Gelatin - chemistry Gelatin - pharmacology Humans Male Mice Mice, Inbred BALB C Mice, Nude Nanoparticles - chemistry Neoplasms, Experimental - drug therapy Neoplasms, Experimental - metabolism Neoplasms, Experimental - pathology Polyethylene Glycols - chemistry Polyethylene Glycols - pharmacology Stomach Neoplasms - drug therapy Stomach Neoplasms - metabolism Stomach Neoplasms - pathology |
| title | Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A03%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Active%20Targeted%20Nanoparticles%20for%20Oral%20Administration%20of%20Gastric%20Cancer%20Therapy&rft.jtitle=Biomacromolecules&rft.au=Lin,%20Yu-Hsin&rft.date=2015-09-14&rft.volume=16&rft.issue=9&rft.spage=3021&rft.epage=3032&rft.pages=3021-3032&rft.issn=1525-7797&rft.eissn=1526-4602&rft_id=info:doi/10.1021/acs.biomac.5b00907&rft_dat=%3Cproquest_cross%3E1727695301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1727695301&rft_id=info:pmid/26286711&rfr_iscdi=true |